目的:观察托吡酯对抽动障碍患儿血清炎症因子水平的影响及疗效。方法:抽动障碍患儿68例分为观察组与对照组各34例。观察组患儿予托吡酯治疗,以0.5～1.0mg·kg~(-1)为起始剂量,每周加量1次,至临床症状消失或达最大剂量5mg·kg~(-1)。对照组患儿予氟哌啶醇治疗,以1.0mg·d~(-1)为起始剂量,每周加量1次,至临床症状消失或达最大剂量6.0 mg·d~(-1)。两组患儿均连用8周。观察两组临床疗效及血浆IL-6、IL-8和TNF-α水平的变化。结果:治疗8周后,两组患儿血浆IL-6、IL-8和TNF-α水平均较治疗前明显升高(P<0.05或0.01),且观察组升高值较对照组更明显(P<0.05)。观察组的临床总有效率明显高于对照组(P<0.05),不良反应的发生率明显低于对照组(P<0.05)。结论:托吡酯治疗儿童抽动障碍的疗效确切,安全性较好,可提高血浆炎症因子IL-6、IL-8和TNF-α水平,从而提高患儿免疫功能及抑制炎症反应。 Objective: To observe the effect of topiramate on the levels of serum inflammatory cytokines in children with tic disorder. Methods: 68 children with tic disorder were divided into observation group and control group, 34 cases each. Patients in the observation group were given topiramate. The dosage was 0.5-1.0 mg · kg -1, once a week, until the clinical symptoms disappeared or the maximum dose was 5 mg · kg -1. Children in the control group were treated with haloperidol, 1.0 mg · d -1 as the starting dose, once a week, until the clinical symptoms disappeared or reached the maximum dose of 6.0 mg · d -1. Two groups of children were used for 8 weeks. The clinical efficacy and plasma levels of IL-6, IL-8 and TNF-α in the two groups were observed. Results: After 8 weeks of treatment, the levels of plasma IL-6, IL-8 and TNF-α in both groups were significantly higher than those before treatment (P <0.05 or 0.01), and the values ​​in the observation group were more obvious than those in the control group (P <0.05). The total effective rate in the observation group was significantly higher than that in the control group (P <0.05), and the incidence of adverse reactions was significantly lower than that in the control group (P <0.05). Conclusion: Topiramate is effective and safe in treating tic disorder in children. It can increase the levels of inflammatory cytokines IL-6, IL-8 and TNF-α in children and improve immune function and inflammatory reaction in children.